- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date, Metastases: AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) - Jul 17, 2023 P2, N=64, Recruiting, The combination was well tolerated (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02581215). Trial primary completion date: Mar 2023 --> Dec 2024
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer. (Pubmed Central) - Jul 14, 2023 Here, we report a core-shell nanoscale coordination polymer (NCP) nanoparticle co-delivering a potent and synergistic combination of oxaliplatin, gemcitabine, and SN38 (OGS), for the treatment of pancreatic cancer in mouse models...OGS treatment achieved 75-91% tumor growth inhibition and prolonged mouse survival by 1.6- to 2.8-folds while minimizing systemic toxicities such as neutropenia, hepatotoxicity, and renal toxicity. This work uncovers a novel and clinically relevant nanomedicine strategy to co-deliver synergistic combination chemotherapies for difficult-to-treat cancers.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Review, Journal, Real-world evidence, Real-world, Metastases: Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. (Pubmed Central) - Jul 13, 2023 There were 12 different types of 'planned' dose modification in FOLFIRINOX ranging 75-100% oxaliplatin, 75-100% irinotecan, 0-100% 5-fluorouracil (5-FU) bolus, and 75-133% 5-FU continuous injection...The pattern of dose modification was not consistent across studies, and there was a significant gap between the 'planned' and 'actual' doses. Modified FOLFIRINOX showed similar efficacy to the standard regimen with reduced incidence of febrile neutropenia.
- |||||||||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 13, 2023 P1/2, N=49, Active, not recruiting, Trial primary completion date: May 2022 --> May 2024 Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2023 --> Oct 2023
- |||||||||| TTX-080 / Tizona Therap
Enrollment closed, Trial primary completion date, Monotherapy: TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) - Jul 12, 2023 P1a/1b, N=240, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: GASTFOX: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA (clinicaltrials.gov) - Jul 12, 2023 P3, N=507, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Apr 2023
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, Metastases: Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. (Pubmed Central) - Jul 12, 2023 Modified fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) regimen (mFOLFIRINOX), comprised of fluorouracil, leucovorin, irinotecan and oxaliplatin, is the first-line standard chemotherapy in patients with advanced pancreatic cancer...The occurrence of any grade 3 to 4 toxicity was similar in the two groups. For locally advanced or metastatic pancreatic cancer patients, the SOXIRI regimen had similar efficacy and controllable safety compared with the mFOLFIRINOX regimen.
- |||||||||| leucovorin calcium / Generic mfg., levetiracetam / Generic mfg., desmopressin / Generic mfg.
Unexplained cerebrospinal fluid findings in GABA transaminase deficiency (Exhibitions Hall (ICC)) - Jul 11, 2023 - Abstract #SSIEM2023SSIEM_615; It is of note that central DI has been described before in this very rare disorder. Further studies are required to understand the CSF biochemistry.
- |||||||||| leucovorin calcium / Generic mfg.
First Late-Onset Cerebral Folate Transporter Deficiency with a Novel Mutation Mimicking SSPE and Wilson (Exhibitions Hall (ICC)) - Jul 11, 2023 - Abstract #SSIEM2023SSIEM_469; Further studies are required to understand the CSF biochemistry. The extremely low CSF 5-methiltetrahyrofolate level confirmed the disease, so he was treated orally with calcium folinate replacement...Even though the EEG showed SSPE or the brain MRI pathologies indicated disorders with metal deposition such as Wilson
- |||||||||| Journal: Cutoff value of IC for drug sensitivity in patient-derived tumor organoids in colorectal cancer. (Pubmed Central) - Jul 10, 2023
We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy...Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits.
- |||||||||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
P3 data, Journal: First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. (Pubmed Central) - Jul 10, 2023 P3 In patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI-bevacizumab was the preferred treatment in patients with a right-sided or RAS or BRAF mutated primary tumour. In patients with a left-sided and RAS and BRAF wild-type tumour, the addition of panitumumab to FOLFOX or FOLFIRI showed no clinical benefit over bevacizumab, but was associated with more toxicity.
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Jul 7, 2023 P2, N=28, Recruiting, However, the second-line treatment demonstrated clear superiority over the best Trial primary completion date: Mar 2023 --> Nov 2023
- |||||||||| leucovorin calcium / Generic mfg.
Cerebral folate deficiency due to DHFR mutation (Exhibitions Hall (ICC)) - Jul 6, 2023 - Abstract #SSIEM2023SSIEM_197; Folinic acid was subsequently started at 1 year of age with seizure control, although his developmental evaluation revealed progressive deterioration... The early intervention in our second child preceding the neurological symptoms, gives us hope for a better outcome
- |||||||||| Graspa (eryaspase) / PHAXIAM Therap
Trial completion date, Trial primary completion date: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 6, 2023 P1, N=19, Active, not recruiting, The early intervention in our second child preceding the neurological symptoms, gives us hope for a better outcome Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2022
|